ELV Elevance Health, Inc.

NYSE elevancehealth.com


$ 324.80 $ -6.38 (-1.93 %)    

Tuesday, 18-Nov-2025 15:58:04 EST
QQQ $ 597.12 $ -7.35 (-1.22 %)
DIA $ 461.67 $ -5.02 (-1.08 %)
SPY $ 660.81 $ -5.59 (-0.84 %)
TLT $ 89.05 $ -0.03 (-0.03 %)
GLD $ 374.31 $ 2.70 (0.73 %)
$ 324.53
$ 329.49
$ 324.77 x 1
$ 325.07 x 13
$ 323.41 - $ 328.95
$ 272.22 - $ 454.26
1,416,162
na
72.12B
$ 0.44
$ 13.04
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-21-2025 09-30-2025 10-Q
2 07-17-2025 06-30-2025 10-Q
3 04-22-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 10-17-2024 09-30-2024 10-Q
6 07-17-2024 06-30-2024 10-Q
7 04-18-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 10-18-2023 09-30-2023 10-Q
10 07-19-2023 06-30-2023 10-Q
11 04-19-2023 03-31-2023 10-Q
12 02-15-2023 12-31-2022 10-K
13 10-19-2022 09-30-2022 10-Q
14 07-20-2022 06-30-2022 10-Q
15 04-20-2022 03-31-2022 10-Q
16 02-16-2022 12-31-2021 10-K
17 10-20-2021 09-30-2021 10-Q
18 07-21-2021 06-30-2021 10-Q
19 04-21-2021 03-31-2021 10-Q
20 02-18-2021 12-31-2020 10-K
21 10-28-2020 09-30-2020 10-Q
22 07-29-2020 06-30-2020 10-Q
23 04-29-2020 03-31-2020 10-Q
24 02-19-2020 12-31-2019 10-K
25 10-23-2019 09-30-2019 10-Q
26 07-24-2019 06-30-2019 10-Q
27 04-24-2019 03-31-2019 10-Q
28 02-20-2019 12-31-2018 10-K
29 10-31-2018 09-30-2018 10-Q
30 07-25-2018 06-30-2018 10-Q
31 04-25-2018 03-31-2018 10-Q
32 02-21-2018 12-31-2017 10-K
33 10-25-2017 09-30-2017 10-Q
34 07-26-2017 06-30-2017 10-Q
35 04-26-2017 03-31-2017 10-Q
36 02-22-2017 12-31-2016 10-K
37 11-02-2016 09-30-2016 10-Q
38 07-27-2016 06-30-2016 10-Q
39 04-27-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hedge-funds-snap-up-eli-lilly-united-healthcare-and-more-putting-healthcare-etfs-back-in-the-spotlight

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensi...

 warren-buffett-disciple-seth-klarman-takes-new-stake-in-railroad-company-lowers-stake-in-this-magnificent-seven-stock

Baupost Group, led by Seth Klarman, made major changes to its investment portfolio in the third quarter. A look at the changes.

 dow-jones-hits-record-highs-amd-jumps-whats-moving-markets-wednesday

Blue-chip stocks hit record highs as investors rotate toward old-economy leaders; AMD surges, gold rallies, oil slides on OPEC ...

 elevance-cfo-says-co-sees-medicaid-margin-declining-at-least-125-bps-in-2026

- Reuters Citing UBS Conference Call

 pete-buttigieg-slams-trumps-bad-deal-on-health-insurance-cites-cbo-estimate-of-10-premium-hikes-losing-on-the-economy

Pete Buttigieg says Trump's ATC attack is a distraction from his "bad deal" on health insurance and failure on "...

 elevance-health-reaffirms-2025-guidance-gaap-eps-2470-adjusted-eps-3000

Officers of Elevance Health, Inc. (the "Company") expect to speak with investors over the next week. During these meeti...

 insurers-slide-as-congress-postpones-decision-on-health-subsidies-delays-obamacare-subsidy-vote-to-december

Health insurer stocks fell after the Senate ended the shutdown without extending ACA subsidies, delaying the decision to Decemb...

 tech-rallies-palantir-jumps-6-as-shutdown-end-looms-whats-moving-markets-monday

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk as...

 mizuho-maintains-outperform-on-elevance-health-lowers-price-target-to-400

Mizuho analyst Ann Hynes maintains Elevance Health (NYSE:ELV) with a Outperform and lowers the price target from $420 to $400.

 jp-morgan-maintains-overweight-on-elevance-health-raises-price-target-to-394

JP Morgan analyst Lisa Gill maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $384 to ...

 inflation-vs-reality-bilello-slams-clearly-wrong-government-data-claiming-health-insurance-prices-fell-18costs-only-go-in-one-direction

Charlie Bilello slams "absurd" gov't data claiming health insurance fell 18%. He says costs "only go in one dir...

 centene-and-oscar-health-stocks-sink-after-molina-warning

US healthcare insurance providers Centene and Oscar Health stocks are down after Molina Healthcare reported disappointing guida...

 td-cowen-maintains-buy-on-elevance-health-raises-price-target-to-380

TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $330 to $380.

 wells-fargo-maintains-overweight-on-elevance-health-lowers-price-target-to-403

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $...

 barclays-maintains-overweight-on-elevance-health-lowers-price-target-to-385

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $395 to ...

 elevance-healths-strong-quarter-cant-shake-off-medicaid-troubles

Elevance Health beats estimates, but shares fall due to Medicare pressures, Obamacare changes, and Medicaid attrition.

 gold-sinks-5-on-worst-day-in-5-years-dow-jones-hits-record-highs-whats-moving-markets-tuesday

Gold prices suffered a sharp correction on Tuesday as investors locked in profits following this year's explosive rally, wh...

 elevance-health-exec-says-the-anticipated-expiration-of-enhanced-subsidies-would-significantly-impact-membership-in-2026-co-is-expanding-behavioral-health-interventions-strengthening-specialty-drug-management-co-is-planning-for-higher-costs-in-its-obamacare-plans-in-q4-as-members-utilize-their-benefits-ahead-of-coverage-changes-next-year-says-2026-will-be-the-low-point-in-medicaid-margins-with-improvement-expected-in-2027

- Conf Call

 elevance-health-raises-fy2025-gaap-eps-guidance-from-2410-to-2470-vs-2524-est

Elevance Health (NYSE:ELV) raises FY2025 GAAP EPS guidance from $24.10 to $24.70 vs $25.24 analyst estimate..

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION